Shares of Avanos Medical Inc (NYSE:AVNS) have been given an average recommendation of “Hold” by the seven analysts that are currently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $63.50.
Several research firms recently commented on AVNS. Zacks Investment Research cut shares of Avanos Medical from a “hold” rating to a “sell” rating in a research report on Tuesday. KeyCorp cut their price objective on shares of Avanos Medical from $67.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 27th. Barclays lowered shares of Avanos Medical from an “equal weight” rating to an “underweight” rating in a research note on Friday, January 4th. Finally, ValuEngine lowered shares of Avanos Medical from a “buy” rating to a “hold” rating in a research note on Monday, March 11th.
A number of hedge funds have recently modified their holdings of AVNS. Vanguard Group Inc acquired a new stake in Avanos Medical in the 3rd quarter valued at $294,519,000. Vanguard Group Inc. acquired a new stake in Avanos Medical in the 3rd quarter valued at $294,519,000. Paradice Investment Management LLC increased its stake in Avanos Medical by 119.5% in the 4th quarter. Paradice Investment Management LLC now owns 1,492,595 shares of the company’s stock valued at $66,853,000 after buying an additional 812,659 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Avanos Medical in the 3rd quarter valued at $52,359,000. Finally, Norges Bank acquired a new stake in Avanos Medical in the 4th quarter valued at $33,253,000. Hedge funds and other institutional investors own 92.45% of the company’s stock.
Avanos Medical (NYSE:AVNS) last posted its quarterly earnings data on Tuesday, February 26th. The company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.24 by $0.09. The business had revenue of $169.90 million for the quarter, compared to analysts’ expectations of $166.88 million. Avanos Medical had a net margin of 8.81% and a return on equity of 7.20%. The firm’s revenue was up 2.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.73 EPS. As a group, equities analysts forecast that Avanos Medical will post 1.25 EPS for the current year.
Avanos Medical Company Profile
Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.
Read More: What is the LIBOR?
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.